|
|
|
|
LEADER |
00000cam a2200000Ii 4500 |
001 |
SCIDIR_ocn903118327 |
003 |
OCoLC |
005 |
20231120111939.0 |
006 |
m o d |
007 |
cr cnu|||unuuu |
008 |
150210s2015 mau ob 001 0 eng d |
040 |
|
|
|a N$T
|b eng
|e rda
|e pn
|c N$T
|d N$T
|d UIU
|d E7B
|d OCLCF
|d UAB
|d D6H
|d OCLCQ
|d OTZ
|d UWO
|d LOA
|d UKBTH
|d K6U
|d COCUF
|d AU@
|d UKCRE
|d LVT
|d OCLCO
|d OCLCQ
|d OCLCO
|
019 |
|
|
|a 1072031211
|a 1081090049
|a 1086572851
|a 1153470841
|a 1229488213
|
020 |
|
|
|a 9780128025932
|q electronic bk.
|
020 |
|
|
|a 012802593X
|q electronic bk.
|
020 |
|
|
|z 9780128024430
|
020 |
|
|
|a 0128024437
|
020 |
|
|
|a 9780128024430
|
035 |
|
|
|a (OCoLC)903118327
|z (OCoLC)1072031211
|z (OCoLC)1081090049
|z (OCoLC)1086572851
|z (OCoLC)1153470841
|z (OCoLC)1229488213
|
050 |
|
4 |
|a QP552.O65
|
072 |
|
7 |
|a SCI
|x 007000
|2 bisacsh
|
082 |
0 |
4 |
|a 572.65
|2 23
|
245 |
0 |
0 |
|a Vitamins and hormones.
|n Volume Ninety-Seven,
|p Nociceptin Opioid /
|c series editor, Gerald Litwack, PhD, Toluca Lake, North Hollywood, California.
|
246 |
3 |
|
|a Vitamins and hormones.
|n Volume 97,
|p Nociceptin opioid
|
246 |
3 |
|
|a Nociceptin opioid
|
250 |
|
|
|a First edition
|
264 |
|
1 |
|a Waltham, MA :
|b Academic Press,
|c 2015.
|
300 |
|
|
|a 1 online resource.
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
347 |
|
|
|a data file
|2 rda
|
490 |
1 |
|
|a Vitamins and hormones ;
|v volume 97
|
588 |
0 |
|
|a Vendor-supplied metadata.
|
504 |
|
|
|a Includes bibliographical references and index.
|
505 |
0 |
|
|a Front Cover; Nociceptin Opioid; Copyright; Contents; Contributors; Preface; Chapter 1: Helix-Constrained Nociceptin Peptides Are Potent Agonists and Antagonists of ORL-1 and Nociception; 1. Nociception in Brief; 1.1. Opioid receptor-like receptor-ORL-1; 1.2. Nociceptin; 1.3. Interrogating the activation and address domains of nociceptin(1-17); 2. Prospecting the Importance of the N-Terminal Tetrapeptide of Nociceptin(1-17); 3. Other Modifications to Nociceptin(1-17); 4. The Importance of Structure in Nociceptin Analogues; 4.1. Importance of helicity; 4.2. Other nociceptin derivatives
|
505 |
8 |
|
|a 5. Recent Advances in ORL-1 Active Nociceptin Peptides6. The Development of New Helix-Constrained Nociceptin Analogues; 6.1. Design of helix-constrained nociceptin analogues; 6.2. Helical structure of nociceptin(1-17)-NH2 analogues in water; 6.3. Nuclear magnetic resonance spectra-derived structures; 7. Biological Properties of Helical Nociceptin Mimetics; 7.1. Cellular expression of ORL-1 and ERK phosphorylation; 7.2. Agonist and antagonist activity of nociceptin(1-17)-NH2 and analogues; 7.3. Effects of helical constraint on biological activity in Neuro-2a cells
|
505 |
8 |
|
|a 7.4. Stability and cell toxicity of helix-constrained versus unconstrained peptides7.5. In vivo activity of helix-constrained versus unconstrained nociceptin analogues; 8. Concluding Remarks; References; Chapter 2: Bioinformatics and Evolution of Vertebrate Nociceptin and Opioid Receptors; 1. Introduction; 1.1. The origin of G protein-coupled receptors; 1.2. A brief history of opioid receptors; 1.3. Evidence for opioid receptors in nonmammalian vertebrates; 2. The Vertebrate Opioid Receptor Sequence Database; 2.1. Alignment of protein sequences
|
505 |
8 |
|
|a 2.2. Phylogenetic analysis of vertebrate opioid receptors2.3. Divergence and convergence of opioid receptor types; 3. The Human Genome and the Evolution of Opioid Receptors; 3.1. Duplicated opioid family receptor genes in the human genome; 3.2. Variation in human opioid receptor genes; 4. The Molecular Evolution of Vertebrate Opioid Family Receptors; 5. Future Directions; 6. Conclusions; Acknowledgments; References; Chapter 3: Ancestral Vertebrate Complexity of the Opioid System; 1. Introduction; 2. Opioid Peptide Family; 3. Opioid Receptor Family
|
505 |
8 |
|
|a 4. Discussion: Complexity, Coevolution, and Divergence5. Conclusions; Acknowledgement; References; Chapter 4: Synthesis and Biological Activity of Small Peptides as NOP and Opioid Receptors' Ligands: View on Current Devel...; 1. Introduction; 2. Endogenous Opioid Peptides and Receptors: Nociceptin and NOP Receptor Ligands; 3. Hexapeptides with NOP Receptor Affinity; 4. Solid-Phase Peptide Synthesis; 5. Conclusions; Acknowledgment; References; Chapter 5: Pain Regulation by Nocistatin-Targeting Molecules: G Protein-Coupled-Receptor and Nocistatin-Interacting Protein; 1. Introduction
|
520 |
|
|
|a First published in 1943, Vitamins and Hormones is the longest-running serial published by Academic Press. The Series provides up-to-date information on vitamin and hormone research spanning data from molecular biology to the clinic. A volume can focus on a single molecule or on a disease that is related to vitamins or hormones. A hormone is interpreted broadly so that related substances, such as transmitters, cytokines, growth factors and others can be reviewed. This volume focuses on nociceptin opioid. Key features: Expertise of the contributorsCoverage of a vast array of subjectsIn.
|
650 |
|
0 |
|a Opioid peptides.
|
650 |
|
0 |
|a Nociceptive pain.
|
650 |
|
6 |
|a Peptides opio�ides.
|0 (CaQQLa)201-0268791
|
650 |
|
7 |
|a SCIENCE / Life Sciences / Biochemistry
|2 bisacsh
|
650 |
|
7 |
|a Nociceptive pain
|2 fast
|0 (OCoLC)fst01909952
|
650 |
|
7 |
|a Opioid peptides
|2 fast
|0 (OCoLC)fst01046543
|
776 |
0 |
8 |
|i Print version:
|t Vitamins and hormones. Volume ninety-seven, Nociceptin opioid.
|b First edition.
|d Waltham, [Massachusetts] : Academic Press, c2015
|h xvi, 357 pages
|k Vitamins and hormones ; Volume 97.
|x 0083-6729
|z 9780128024430
|
830 |
|
0 |
|a Vitamins and hormones ;
|v volume 97.
|
856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780128024430
|z Texto completo
|